LRMR - NASDAQ
Larimar Therapeutics, Inc.
$3.30
-3.0%Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
At a Glance
Live SnapshotNo Revenue Data
LRMR has not reported any revenue values in the available annual periods.
Larimar Therapeutics, Inc. Profit Bridge
Profitability Analysis
Larimar Therapeutics, Inc. Income Statement
LRMR • NASDAQ
| Larimar Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
GROSS PROFIT | |||||||||||||||
(350K) | (0.0) | (0.0) | (0.0) | (0.0) | (155K) | (78K) | (261K) | (188K) | (212K) | (70K) | (0.0) | (12K) | (11K) | (4K) | |
-350K | 0.0 | 0.0 | 0.0 | 0.0 | -155K | -78K | -261K | -188K | -212K | -70K | 0.0 | -12K | -11K | -4K | |
OPERATING INCOME | |||||||||||||||
(172.5M) | (90.9M) | (41.8M) | (36.5M) | (50.5M) | (42.6M) | (23.2M) | (62.5M) | (53.7M) | (56.9M) | (73.7M) | (35.5M) | (13.8M) | (13.8M) | (13.2M) | |
(18.3M) | (17.6M) | (14.1M) | (12.3M) | (12.1M) | (11.4M) | (2.4M) | (12.9M) | (11.9M) | (17.1M) | (19.1M) | (8.1M) | (4.2M) | (2.2M) | (1.7M) | |
(154.2M) | (73.3M) | (27.7M) | (24.3M) | (38.4M) | (31.3M) | (20.8M) | (49.5M) | (41.7M) | (39.8M) | (54.6M) | (27.4M) | (9.6M) | (11.5M) | (11.4M) | |
-172.5M | -90.9M | -41.8M | -36.5M | -50.5M | -42.8M | -23.2M | -62.7M | -53.9M | -57.1M | -73.8M | -35.5M | -13.8M | -13.8M | -13.2M | |
PRE-TAX INCOME | |||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (971K) | (347K) | (806K) | -870K | (0.0) | (97K) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 25K | 547K | -368K | 898K | 0.0 | -97K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (82K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
6.8M | 10.3M | 4.8M | 1.2M | -171K | 322K | 82K | -246K | 947K | -1.1M | -473K | -1M | -247K | -89K | -3K | |
-165.7M | -80.6M | -36.9M | -35.4M | -50.6M | -42.5M | -23.1M | -63M | -52.9M | -58.2M | -74.3M | -36.6M | -14M | -13.9M | -13.2M | |
NET INCOME | |||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -93.9K | -1.6M | -900K | -300K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-165.7M | -80.6M | -36.9M | -35.4M | -50.6M | -42.3M | -23.1M | -61.4M | -52M | -57.9M | -74.3M | -36.6M | -14M | -13.9M | -13.2M |
SEC Filings
LRMR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | April 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 21, 2026 | 2026 |
Related Guides
Continue your LRMR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.